Multiple myeloma and its treatment contribute to increased platelet reactivity
Last Updated: Thursday, November 16, 2023
Abstract
With lenalidomide treatment of multiple myeloma (MM), smoldering myeloma, and monoclonal gammopathy of undetermined significance associated with increased incidence of thrombotic risk by an unknown mechanism, this pilot study aimed to establish the impact of MM and its treatment with lenalidomide on platelet function.
Advertisement
News & Literature Highlights